Compare BYAH & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYAH | INDP |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | China | United States |
| Employees | N/A | 7 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.7M |
| IPO Year | 2024 | N/A |
| Metric | BYAH | INDP |
|---|---|---|
| Price | $0.12 | $2.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 233.1K | ★ 435.6K |
| Earning Date | 02-24-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,768,120.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.65 | N/A |
| 52 Week Low | $0.14 | $1.65 |
| 52 Week High | $41.49 | $47.60 |
| Indicator | BYAH | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 24.17 | 44.85 |
| Support Level | $0.15 | $2.60 |
| Resistance Level | $0.17 | $3.66 |
| Average True Range (ATR) | 0.01 | 0.30 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 5.30 | 7.20 |
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.